Clinical Trials for Refractory Lymphoma

Find clinical trials for refractory lymphoma. Discover research opportunities and treatment options in your area.

15 Active Trials Found

Showing 15 trials on this page

Page 1 of 1

Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma. Substudy B: CLL Patients

NCT ID: NCT06916767

This clinical trial is testing a new treatment called LMY-920, which uses modified immune cells (CAR-T cells) to fight chronic lymphocytic leukemia (CLL) in patients whose disease has not responded...

Not yet recruiting

Phase: PHASE1 Type: interventional Locations: Cleveland, Ohio, United States

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas

NCT ID: NCT05053971

This clinical trial is exploring a new combination of two anti-cancer drugs, entinostat and ZEN003694, to see how safe they are and how well they work for patients with advanced solid tumors or lym...

Recruiting

Phase: PHASE1 Type: interventional Locations: New Haven, Connecticut, United States, Oklahoma City, Oklahoma, United States +2 more

GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL

NCT ID: NCT06875063

This clinical trial is studying a new treatment called GB5005, which is an injection of modified immune cells designed to help patients with a type of blood cancer known as CD19-positive relapsed/r...

Recruiting

Phase: PHASE1 Type: interventional Locations: Xiamen, Fujian, China

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

NCT ID: NCT04870944

This clinical trial is studying a new treatment called CBL0137 for young patients with certain types of solid tumors, including cancers of the central nervous system (CNS) and lymphoma that have ei...

Recruiting

Phase: PHASE1 Type: interventional Locations: Durham, North Carolina, United States, Philadelphia, Pennsylvania, United States +32 more

Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma

NCT ID: NCT06826118

This clinical trial is studying a new treatment called Axicabtagene Ciloleucel Injection for patients with a type of cancer known as relapsed or refractory follicular lymphoma. This means the lymph...

Recruiting

Phase: PHASE2 Type: interventional Locations: Xiamen, Fujian, China

Avo In R/R And Previously Untreated MCL

NCT ID: NCT04855695

This clinical trial is investigating a new treatment approach for mantle cell lymphoma (MCL), which is a type of blood cancer. The study is testing a combination of three medications: acalabrutinib...

Recruiting

Phase: PHASE1 Type: interventional Locations: Boston, Massachusetts, United States, Boston, Massachusetts, United States +1 more

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

NCT ID: NCT03418038

This clinical trial is studying the combined effect of ascorbic acid (a form of vitamin C) and chemotherapy on patients with certain types of lymphoma that have either come back after treatment or ...

Recruiting

Phase: PHASE2 Type: interventional Locations: Scottsdale, Arizona, United States, Iowa City, Iowa, United States +5 more

Epcoritamab, Zanubrutinib, and Rituximab (EZR) for R/R FL Relapsed or Refractory Follicular Lymphoma

NCT ID: NCT06563596

This clinical trial is studying a combination of three medications—epcoritamab, zanubrutinib, and rituximab— to see how well they work together in treating patients with relapsed or refractory foll...

Recruiting

Phase: PHASE2 Type: interventional Locations: Boston, Massachusetts, United States, Boston, Massachusetts, United States

Solving Riddles Through Sequencing

NCT ID: NCT05046444

The clinical trial titled "Solving Riddles Through Sequencing" is investigating how advanced genetic testing methods can help doctors better diagnose certain types of blood cancers, such as leukemi...

Recruiting

Type: observational Locations: Munich, , Germany

A Study of HDM2005 in Patients With Relapsed/Refractory B-cell Lymphoma and Advanced Solid Tumor

NCT ID: NCT06615193

This clinical trial is studying an experimental drug called HDM2005 to see how safe it is and whether it can help patients with certain types of cancer, specifically relapsed or refractory B-cell l...

Recruiting

Phase: PHASE1 Type: interventional Locations: Suzhou, Jiangsu, China, Zhengzhou, Henan, China +8 more

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

NCT ID: NCT06004167

This clinical trial is looking at a new way to give radiation therapy to patients with certain types of B-cell lymphoma that have either come back after treatment or didn’t respond to it. The goal ...

Recruiting

Phase: NA Type: interventional Locations: Boston, Massachusetts, United States, Boston, Massachusetts, United States +1 more

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

NCT ID: NCT04470947

The EXALT-2 clinical trial is studying new treatment options for patients with aggressive blood cancers such as advanced lymphoma and leukemia that have not responded to previous therapies. This tr...

Recruiting

Type: observational Locations: Vienna, , Austria

Salvage Treatment With Glofitamab in R/R B-NHL: a GIMEMA-FIL Study

NCT ID: NCT05927558

This clinical trial is looking at how well a treatment called glofitamab works for patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma, which is a type of cancer that affects the lymph...

Recruiting

Type: observational Locations: Milano, , Italy

Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia

NCT ID: NCT05576532

This clinical trial is studying a combination treatment of Venetoclax and the IM2 regimen for patients with T-lymphoblastic lymphoma or leukemia that has come back after treatment or did not respon...

Recruiting

Phase: PHASE2 Type: interventional Locations: Shanghai, Shanghai, China

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

NCT ID: NCT04994626

This clinical trial is looking at a new treatment approach for patients with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has not responded to previous therapies. Specif...

Not yet recruiting

Phase: PHASE2 Type: interventional

Related Conditions

Breast Cancer View clinical trials → Stroke View clinical trials → Obesity View clinical trials → Cancer View clinical trials → Healthy View clinical trials → Prostate Cancer View clinical trials →

Search All Trials Browse All Conditions